Shehla Admani, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Admani’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A122465 · Current
Licensed to practise in California · since 2012 · expires 2028-03-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$6,965
Medicare paid this office $6,965 for 42 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 32 | $4,557 | $79 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 14 | $237 | $15 |
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
42 Original Medicare patients in 2024. Average age 74 · Health risk score 1.43. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 67% · Chronic kidney disease 29% · Depression 26%.
The office billed $18,153, Medicare allowed $9,571 and paid $6,965; for 101 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 42 | 101 | 74 | 1.43 | $18,153 | $6,965 |
| 2023 | 35 | 73 | 75 | 1.08 | $10,068 | $6,038 |
| 2022 | 34 | 71 | 73 | 1.70 | $14,494 | $5,489 |
| 2021 | 25 | 65 | 73 | 1.07 | $14,982 | $5,171 |
| 2020 | 29 | 81 | 73 | 1.47 | $32,658 | $4,955 |
| 2019 | 93 | 453 | 75 | 1.48 | $227,239 | $19,182 |
| 2018 | 51 | 185 | 74 | 0.92 | $97,545 | $8,933 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 28 | $4,238 | $77 |
2022: 1 service
| Return visit (30+ min) | 19 | $2,997 | $73 |
2021: 1 service
| Return visit (30+ min) | 19 | $2,405 | $80 |
2020: 1 service
| Return visit (30+ min) | 15 | $1,500 | $83 |
2019: 7 services
| Return visit (30+ min) | 45 | $5,415 | $97 |
| Short return visit (20+ min) | 44 | $2,803 | $52 |
| New patient visit (30+ min) | 19 | $1,777 | $94 |
| Destruction of precancer skin growth, 1 growth | 30 | $1,653 | $42 |
| Biopsy of related skin growth, first growth | 23 | $1,616 | $62 |
| Destruction of skin growth, 1-14 growths | 12 | $1,155 | $89 |
| Destruction of precancer skin growth, 2-14 growths | 26 | $1,008 | $5 |
2018: 5 services
| Return visit (30+ min) | 25 | $2,553 | $98 |
| New patient visit (30+ min) | 14 | $1,370 | $98 |
| Destruction of precancer skin growth, 1 growth | 22 | $1,055 | $48 |
| Biopsy of single growth of skin and/or tissue | 14 | $1,027 | $73 |
| Destruction of precancer skin growth, 2-14 growths | 16 | $401 | $5 |
Medicaid work
$35,160 in 2024
Medicaid paid $35,160 for 327 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 251 | $33,251 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 29 | $1,480 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 47 | $429 |
| 2024 | 327 | 3 | 33 | $35,160 |
| 2023 | 316 | 2 | 36 | $27,844 |
| 2022 | 359 | 2 | 34 | $28,416 |
| 2021 | 384 | 3 | 39 | $25,072 |
| 2020 | 263 | 3 | 31 | $18,763 |
| 2019 | 87 | 3 | 22 | $5,004 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 304 | $27,486 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 12 | $359 |
2022
| Return visit (30+ min) | 347 | $28,338 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 12 | $78 |
2021
| Return visit (30+ min) | 344 | $21,857 |
| New patient visit (45+ min) | 26 | $2,833 |
| Short return visit (20+ min) | 14 | $382 |
2020
| Return visit (30+ min) | 224 | $16,674 |
| Short return visit (20+ min) | 27 | $1,550 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 12 | $539 |
2019
| Return visit (30+ min) | 48 | $2,630 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 13 | $1,319 |
| Short return visit (20+ min) | 26 | $1,056 |
Drugs they prescribed that Part D paid
$49,837
Pharmacies billed $49,837 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 124) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
113 generic and 11 brand-name prescriptions · $49,837 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 24 | $1,888 | $79 |
| Fluocinonide | 11 | $273 | $25 |
| Triamcinolone Acetonide | 15 | $102 | $7 |
Year by year
| 2024 | 124 | 34 | 0% (0) | 9% | $49,837 |
| 2023 | 94 | 33 | 0% (0) | None | $6,034 |
| 2022 | 85 | 31 | 0% (0) | None | $4,187 |
| 2021 | 58 | 20 | 0% (0) | None | $3,321 |
| 2020 | 61 | 26 | 0% (0) | None | $3,745 |
| 2019 | 171 | 57 | None | 6% | $15,308 |
| 2018 | 41 | 30 | 0% (0) | None | $4,242 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Clobetasol Propionate | 14 | $589 | $42 |
| Triamcinolone Acetonide | 14 | $109 | $8 |
2022: 1 drug
| Clobetasol Propionate | 27 | $2,035 | $75 |
2021: 2 drugs
| Clobetasol Propionate | 18 | $998 | $55 |
| Triamcinolone Acetonide | 16 | $96 | $6 |
2020: 2 drugs
| Clobetasol Propionate | 13 | $1,217 | $94 |
| Triamcinolone Acetonide | 18 | $171 | $9 |
2019: 3 drugs
| Clobetasol Propionate | 25 | $4,151 | $166 |
| Ketoconazole | 22 | $385 | $18 |
| Triamcinolone Acetonide | 31 | $319 | $10 |
Money from drug and device companies
$15,627 in 2025
| 2025 | 6 | 13 | $15,421 | $15,627 |
| 2024 | 2 | 2 | None | $124 |
| 2023 | 1 | 3 | None | $270 |
| 2022 | 1 | 1 | None | $23 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| LEO Pharma AS | None | $6,971 | 3 payments
|
| Lilly USA | Ebglyss | $4,707 | 3 payments
|
| Arcutis Biotherapeutics | Zoryve | $3,750 | 2 payments
|
| Novartis Pharmaceuticals | Vijoice | $145 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $28 | 1 payment
|
| Almirall | Seysara | $25 | 1 payment
|
See all 13 published payments
| LEO Pharma AS | Consulting · 2025-12-03 | None | $1,056 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | Vijoice | $112 |
| LEO Pharma AS | Consulting · 2025-06-18 | None | $2,535 |
| Arcutis Biotherapeutics | Consulting · 2025-05-09 | Zoryve | $1,500 |
| Almirall | Meals · 2025-04-24 | Seysara | $25 |
| Arcutis Biotherapeutics | Consulting · 2025-04-03 | Zoryve | $2,250 |
| Novartis Pharmaceuticals | Meals · 2025-02-05 | Vijoice | $28 |
| Novartis Pharmaceuticals | Meals · 2025-02-05 | Vijoice | $5 |
| Lilly USA | Consulting · 2025-01-30 | Ebglyss | $2,500 |
| Lilly USA | Consulting · 2025-01-30 | Ebglyss | $2,200 |
| Regeneron Healthcare Solutions | Meals · 2025-01-22 | Dupixent | $28 |
| Lilly USA | Meals · 2025-01-21 | Taltz | $7 |
| LEO Pharma AS | Consulting · 2025-01-15 | None | $3,380 |
See earlier years (2024, 2023, 2022)
2024: $124
| Novartis Pharmaceuticals | Vijoice | $109 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2023: $270
| Arcutis Biotherapeutics | None | $270 | 3 payments
|
2022: $23
| Galderma Laboratories L.P. | Epsolay | $23 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1073805248
- Licence
- CA A122465California A122465: Current · expires 2028-03-31
- Trained
- University of California, Irvine, California College of Medicine, 2011
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207NP0225X (207NP0225X); Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St # B, Redwood City, CA, 94063
- NPI first listed
- 2011-05-06
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 101 the City Dr S, Orange, CA, 92868 · 450 Broadway St # B, Redwood City, CA, 94063